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Abstract 
Background: Differential diagnosis of thyroid lesions with predominantly follicular pattern is one of the most common problems in thyroid 
pathology.  Development of more objective and reproducible tools for diagnosis is needed. This work is aimed at studying the role of 
nuclear morphometry in differential diagnosis of different thyroid lesions having predominant follicular pattern. 
Material and methods: Semiautomatic image analysis system was used to measure a total of 8 nuclear parameters in 48 thyroid lesions 
including seven nodular goiter (NG), 14 follicular adenoma (FA), 14 follicular carcinoma (FC) and 13 follicular variant papillary carcinoma 
(FVPC). 
Results: The parameters related to nuclear size (area, perimeter, MaxD, MinD, nuclear size) and shape (L/S ratio, Form_AR) were 
significantly higher in neoplastic group (FA, FC, FVPC) when compared to non-neoplastic group (NG) P<0.05.  The perimeter was the 
most reliable parameter (area under the cure (AUC)=97%) followed by area, MaxD, and size (all have AUC= 96%) then form-AR (90%), 
LS ratio (86%) and the least reliable was Min D (79%). Within the neoplastic group, most parameters related to size and shape of the 
nuclei was significantly higher in FVPC than in FA and FC (p ≤ 0.05).  Nuclear area and size (AUC 77%) were the most reliable 
parameters for differentiation between FVPC and FA.   The best cut off values for diagnosing FVPC are nuclear area ≥39.9µm
2 and 
nuclear size ≥27.7µm
2.  However, there was no quantitative difference between FC and FA. 
Conclusion: Nuclear morphometric parameters may help in the differentiation between neoplastic and non-neoplastic thyroid lesions 
and between FVPC and follicular neoplasms (FC and FA) but they have no value in the differentiation between FC and FA. 
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Background 
Differential diagnosis of thyroid lesions with predominantly 
follicular pattern is one of the most common problems in thyroid 
pathology [1,2]. Minimally, invasive follicular carcinomas (FC) 
can be difficult to distinguish from follicular adenomas (FA) by 
histopathology, since the diagnosis of malignancy depends 
entirely on the unequivocal demonstration of capsular and/or 
vascular invasion [3]. Of these, capsular invasion remains a 
highly controversial issue [4]. Immunohistochemical staining for 
markers such as galectin-3 [5] and HBME-1 [6] have been 
suggested as good indicators of thyroid malignancy, although 
they are not used as absolute markers of malignancy [7]. The 
follicular variant of papillary thyroid carcinoma (FVPC) is the 
most common histological subtype of papillary thyroid 
carcinoma (PC), constituting up to 24% [8]. The 
histopathological diagnosis of the FVPC is based on the 
characteristic nuclear features of PC and invasive growth or 
lymph node metastases [9]. However, one-third of these 
tumours are totally encapsulated and show no extension 
beyond the thyroid gland [10]. To complicate the situation 
further, some FVPC exhibit indicative nuclear features, such as 
ground glass appearance, only focally, a characteristic common 
of benign lesions, especially those fixed in high-concentration 
formalin [11]. Even at the molecular level, FVPC express certain 
oncogenes in common with follicular tumours [12]. As a result, 
histopathological diagnosis of the encapsulated FVPC remains 
one of the most difficult and controversial areas in thyroid 
surgical pathology [1]. Correct diagnosis in such cases is 
important since FVPC has the potential for lymphatic and 
distant metastases [13]. Also, misdiagnosis of an FA as an 
FVPC will expose the patient to unnecessary aggressive 
surgical intervention. 
Computerized nuclear morphometry is a cost-effective, 
objective and reproducible tool for evaluation of histological 
features [14]. Using nuclear morphometry, we can quantify a 
number of parameters such as those related to nuclear size and 
shape. The evaluation of these parameters has been claimed to 
facilitate the diagnosis and management of different neoplasms, 
including urinary bladder carcinoma [15], skin lymphoma [16], 
breast carcinoma [17] and soft tissue sarcoma [18]. It has been 
suggested that nuclear morphometric parameters such as 
nuclear area and perimeter [19,20], nuclear area coefficient of 
variation [21] and shape factors [22,23] may allow differentiation 
between thyroid lesions. Nevertheless, the use of morphometric 
analysis in thyroid pathology is still very limited in clinical 
research and does not extend to routine histopathological 
diagnosis.  
 
Aim of the study 
The aim of this work was to study the role of nuclear 
morphometry in differential diagnosis of different thyroid lesions 
having a predominantly follicular pattern.  
 
Materials and methods 
Case selection 
Forty-eight cases of different thyroid lesions were studied 
retrospectively. Seven cases of nodular goiter (NG), 14 cases of 
FA, 14 cases of FC (ten of them were minimally invasive) and 
13 cases of FVPC (three were the encapsulated variant. We 
also measured the nuclei of normal thyrocytes from normal 
thyroid tissue adjacent to hyperplastic nodules from the seven 
NG cases. All these cases were retrieved from archives of the 
Pathology Department, Faculty of Medicine, Menoufiya 
University during the period 1998–2002. We selected the cases 
on the basis of the presence of a predominant follicular pattern, 
excluding those with architectural features of classic PC or 
oncocytic neoplasms. The histological sections were examined 
by at least two pathologists who agreed the final diagnoses. 
FVPC and its encapsulated type were diagnosed according to 
criteria described by Tielens et al [9] and Chan et al [10]. For 
follicular carcinoma, unequivocal histological evidence of 
vascular and/or capsular invasion was documented. Follicular 
adenoma cases did not show any evidence suggestive of either 
vascular or capsular invasion regardless of nuclear atypical 
features. To standardize the process, new 4 µ-paraffin sections 
were prepared by the same technician, using the same 
microtome. Morphometric analysis was performed blind, that is 
without any knowledge of the diagnosis. 
Image analysis system 
The image analyser is a semi-automatic system composed of a 
trinocular microscope (Olympus Corporation, Japan), a digital 
video camera (Panasonic, Japan) and a personal computer 
(Toshiba, Japan). The computer is equipped with 3.66 GHz 
processor with 1022 MB RAM, 160-GB hard disk, NVIDIA 
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Figure 1: An example of a follicular variant papillary carcinoma image in the Digimizer program window, showing yellow tracing of the nuclei 
borders and the corresponding area and perimeter values (hematoxylin and eosin x1000, original magnification).
Geforce 7600 display adapter, mouse, keyboard, a 17″ high-
resolution colour monitor 
System calibration 
Morphometric measurements were performed with the help of 
Digimizer program version 2. Measurements were calibrated in 
terms of micrometre, using a Nikon micrometre slide before 
performing any measurements. An image to the slide-stage 
micrometre (at magnification x1000) was captured and saved 
on the computer in a JPG file format. The image was used for 
calibration by opening in Digimizer program window. A straight 
line measuring 10 µm was copied and pasted to the image for 
calibration.  
Data collection 
From the subjectively selected areas, an average of 5–10 
microscopic fields, at magnification x1000 were captured for 
each case. At least 100 nuclei were analysed per slide. Care 
was taken to include only intact whole nuclei from the actual 
lesion, avoiding the nuclei of stromal cells. Overlapped and 
fragmented nuclei were discarded. A total of eight nuclear 
morphometric parameters were estimated. An actual 
measurement of four of the nuclear parameters was carried out 
using the drawing tools in the Digimizer program followed by 
data extraction and calculation of the remaining four 
parameters. The measured parameters included: nuclear area 
(expressed in µm
2), nuclear perimeter (expressed in µm), 
maximal nuclear diameter (MaxD) and minimal nuclear diameter 
(MinD) (Figures 1 and 2]. The calculated parameters included 
nuclear size (2 x (nuclear area / π)
0.5) and the coefficient of 
variation of the nuclear area (NACV) (SD of nuclear area/mean 
nuclear area x100) expressed as a percentage [21]. The shape 
factors are calculated by the following formulas; the L/S ratio = 
MaxD/minD [22] and Form_AR = (1/4) * π * longest axis * 
shortest axis [17]. In a round circle, the L/S ratio corresponds to 
one. If the object is elliptic, the L/S ratio is higher than one [22]. 
Statistical analysis 
The data were coded, entered and processed using the SPSS 
(version 15) computer program. The level p ≤ 0.05 was 
considered the cut-off value for significance. Differences 
between groups were analysed with the unpaired t test. We 
constructed receiver operating characteristic (ROC) curves for 
the morphometric parameters in order to select cut-off values 
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Figure 2: An example of a follicular variant papillary carcinoma image in the Digimizer program window. Diameters of the yellow circles indicate 
the maximal nuclear diameters (MaxD), while diameters of green circles indicate minimal nuclear diameters (MinD), (hematoxylin and eosin 
x1000, original magnification).
that best combined sensitivity and specificity for diagnosis of 
thyroid neoplasia and for diagnosis of FVPC.  
 
Results 
The age of the malignant group (14 FC and 13 FVPC) ranged 
between 13 and 76 years with a mean ± SD (51.59 ± 14.88). 
Most of the malignant cases were female with M:F ratio 8:19. 
The tumour size of malignant cases ranged between 0.3 and 9 
cm with a mean ± SD (4.18 ± 2.94). Extra thyroid extension was 
observed in 10/27 (37%) malignant cases and metastasis was 
documented in 3/27 (11%). Follicular carcinoma included ten 
minimally and four widely invasive carcinomas. 
Nuclei of normal thyrocytes from normal thyroid tissue adjacent 
to hyperplastic nodules show area, perimeter, MaxD, MinD, L/S 
ratio, NACV, Nuclear size and Form_AR as follow: 19.43 ± 2.76, 
15.15 ± 1.13, 4.49 ± 0.18, 4.21 ± 0.55, 1.12 ± 0.15, 21.11 ± 
4.93, 4.97 ± 0.34, 14.85 ± 1.92, respectively. These values were 
not significantly different from those of nuclei of NG cells (p > 
0.05). 
The neoplastic group (FA, FC, FVPC) showed significantly 
higher mean values of nuclear parameters related to size (area, 
perimeter, MaxD, MinD, nuclear size) and shape (L/S ratio, 
Form_AR) when compared to the non-neoplastic group (nodular 
goiter) p < 0.05 (Table 1). 
Within the neoplastic group, parameters related to size (area, 
perimeter, MaxD, nuclear size) and shape of the nuclei 
(Form_AR) were significantly higher in FVPC than in FA and FC 
(p  ≤ 0.05) (Table 2 ). However, there was no significant 
difference between FA and FC as regards parameters related to 
either size or shape (p > 0.05). 
According to the ROC curve (Figure 3, Table 3), the perimeter 
was the most reliable parameter for differentiating neoplastic 
from non-neoplastic lesions (area under the curve (AUC) = 
97%) (95% CI 91–100%) followed by area, MaxD and size (all 
have AUC = 96%) (95% CI 91–100%, 90–100% and 91–100%). 
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Table 1: Comparison of nuclear morphometric parameters between non-neoplastic and neoplastic groups  
 
 
Table 2: Comparison of nuclear morphometric parameters within the neoplastic group 
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Table 3: The best cut-off values selected for diagnosis of thyroid neoplasia 
 
 
Figure 3: Receiver operating characteristic curve for differentiation of neoplastic from non-neoplastic thyroid lesions. 
Form-AR (90%), LS ratio (86%) (95% CI 65–100%) and last of 
all MinD (79%) (95% CI 65–94%) p < 0.05 were the least 
reliable. The NACV was not reliable for diagnosing thyroid 
neoplasia (AUC = 52%) (95% CI 30–74%) p > 0.05. The best 
cut-off values for the reliable parameters and their diagnostic 
validity are listed in Table 3. 
According to the ROC curve for differentiation of FVPC from FA, 
nuclear area and size were the most reliable parameters (AUC 
= 77%) (Figure 4,  Table 4 ). The best cut-off values for 
diagnosing FVPC are nuclear area ≥ 39.9 µm
2 and nuclear size 
≥ 27.7 µm
2. The diagnostic validity of these values is shown in 
Table 5 . For differentiation of FVPC from FC, all parameters 
were fair as the AUC for all were less than 75% and no cut-off 
value was selected. 
 
Discussion 
The subjective evaluation of cytological atypical features is not a 
reliable criteria for malignancy in thyroid lesions since these 
changes may be present in benign lesions such as 
adenomatous hyperplasia and follicular adenoma [1]. Therefore, 
it is important to find an objective morphological analysis to 
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Table 4: The diagnostic reliability of different nuclear parameters in differentiation of FVPC from FA  
 
 
Figure 4: Receiver operating characteristic curve for differentiation of FVPC from FA 
allow differential diagnosis between benign and malignant 
lesions in the thyroid gland. In this study, we estimated different 
nuclear morphometric parameters in thyroid lesions that pose 
diagnostic problems in thyroid pathology. We selected lesions 
showing follicular pattern excluding those with architectural 
features of classic PC. Oncocytic neoplasms were also 
excluded because these constitute distinct entities [23]. In our 
nuclear morphometric analysis, parameters related to both size 
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Table 5: Cut-off values and sensitivity and specificity of nuclear area and size in differentiation of FVPC from FA 
and shape of the nuclei were significantly higher in neoplastic 
than non-neoplastic groups (nodular goiter). An ROC curve 
confirmed the reliability of most of the studied nuclear 
parameters in predicting the neoplastic nature of the lesion. Our 
findings agree with previous studies supporting the validity of 
morphometry in diagnosis of thyroid neoplasia [24,25]. More 
importantly, we could statistically select cut-off values suitable 
for diagnosing thyroid neoplasia with increased sensitivity and 
specificity. More studies are recommended to test the validity of 
such cut-off values in histopathological and cytological 
preparations to prove its diagnostic utility. 
In the current study, the nuclei of FVPC were significantly larger 
than those of follicular neoplasms (FA and FC). Similarly, 
previous morphometric studies succeeded in discrimination of 
papillary carcinoma in general or its follicular variant in particular 
from follicular neoplasms [23, 24, 26]. The differentiation 
between encapsulated FVPC and FA is one of the documented 
problems in thyroid pathology [1–3]. The completely 
encapsulated FVPC still carry the potential of lymph node and 
distant metastasis [13]. The term ‘well-differentiated tumour of 
uncertain malignant potential’ has been recommended for 
encapsulated follicular tumours with suggestive nuclear features 
of PC [27]. Many immunohistochemical stains were suggested 
as markers of PC. Cytokeratin 19 is one of the promising 
markers, but it is also positive in significant number of benign 
lesions and at sites of previous biopsy [28,29]. Immunostaining 
for RET to identify RET/PTC rearrangement was also reported, 
but it still is dependant on availability of reliable and sensitive 
antibodies [30]. In the current study, the nuclei of FVPC were 
significantly larger and more irregular in shape than those of FA 
and the ROC curve demonstrated the reliability of nuclear area 
and size in diagnosing FVPC. Moreover, we suggested cut-off 
values ≥ 39.9 µm
2 and ≥ 27.7 µm
3 for nuclear area and size, 
respectively, with best sensitivity and specificity. Our findings 
demonstrate that quantitative measurements of nuclear 
parameters may disclose more features than that can be 
detected by the pathologistís subjective examination. Applying 
such cut-off values could be a more reproducible and objective 
method compared to the subjective detection of papillary 
nuclear features. It is probably more cost-effective than 
immunohistochemistry and may avoid some of the errors 
associated with this technique. 
The FC can be difficult to distinguish from FVPC. In a number of 
follicular tumours with definite capsular and vascular invasion, 
the nuclei may show features suggestive of PC. The diagnosis 
of ‘well-differentiated carcinoma not otherwise specified’ was 
proposed for those tumours [27]. Reviewing the literature, some 
studies did not find a difference between nuclear parameters in 
papillary and follicular carcinomas [26, 31]. In contrast, 
Karslioğlu  et al found that most of the parameters related to 
nuclear size, but not nuclear shape was significantly higher in 
PC than FC in cytological samples [23]. In our study, nuclei of 
FVPC did show significant difference from those of FC; 
however, we could not select suitable cut-off values as all the 
parameters showed AUC less than 75%. Although the clinical 
behaviour of FVPC is better than FC [8], the distinction between 
both tumours may be clinically irrelevant since the treatment is 
similar and depends upon the extent of invasion [32]. 
We showed that quantitative nuclear assessment did not help 
much to solve the problem of differentiating FC from FA. 
Similarly, some studies concluded that there was considerable 
overlap of nuclear morphometric parameters between FC and 
FA [25,33]. Gupta et al studied different nuclear morphometric 
parameters in thyroid lesions and showed highly significant 
differences between benign and malignant groups; however, the 
lowest sensitivity and specificity in their study was documented 
between FC and FA [24]. In contrast, others had found 
significant differences between both tumours using quantitative 
analysis [23, 31, 34, 35]. In our study, the inclusion of FA cases 
showing some atypical nuclear features may be responsible for 
the absence of significant differences between FA and FC, 
while exclusion of these cases from the previous studies may 
affect their findings [23,31]. 
In the present study, we used a semi-automatic system that 
could be easily constructed in any pathology laboratory. The 
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morphometric measurements for each case took approximately 
30–45 min. There is no doubt that automated image analysers 
could perform these measurements much quicker, but due to 
their cost we resorted to the partially automated approach. In 
addition, even with the automatic image analysers, we need to 
manually trace the nuclei to avoid the complexity of histological 
images. For example, some nuclei may not be easily delineated 
if their edges blend into the light density of the cytoplasm [36]. 
 
Conclusion 
Our results draw the attention to the use of nuclear 
morphometry in the diagnosis of difficult follicular-patterned 
lesions of the thyroid gland. Nuclei of neoplastic group showed 
significantly higher values than those of non-neoplastic group. 
Although nuclei of FVPC showed significant quantitative 
difference in size and shape from those of FC and FA, we could
achieve sharp cut-off values between FVPC and FA only. The 
most reliable parameters are the nuclear area and size. Lesions 
with a mean nuclear area ≥ 39.9 µm
2 and a mean nuclear size ≥ 
27.7 µm
2 are most probably papillary carcinoma rather than FA. 
We agree that our figures cannot serve as absolute diagnostic 
criteria since they are only based on statistical differences. 
However, further application on larger studies to find suitable 
cut-off numerical values would open the gate for application of 
quantitative evaluation in the routine diagnostic pathology of 
thyroid lesions. 
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